[PDF] Top 20 Rev. Bras. Hematol. Hemoter. vol.35 número3
Has 10000 "Rev. Bras. Hematol. Hemoter. vol.35 número3" found on our website. Below are the top 20 most common "Rev. Bras. Hematol. Hemoter. vol.35 número3".
Rev. Bras. Hematol. Hemoter. vol.35 número3
... This it does by a points system where articles that are not published in ISI are assigned a very low number of points and only three articles are included in an author’s scientiic prod[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número3
... Aim : The objective of this study was to critically analyze data of the National Notiication System for Adverse Events and Technical Complaints (Notivisa) related to central venous cath[r] ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.35 número3
... NAT and serology: In the last two years (2010 and 2011) the prevalence of infectious markers among the screened blood donors remained stable. Overall, there were 275 (1.12%) donations discarded due to the presence of ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.35 número3
... entitled “Alpha chain hemoglobins with electrophoretic mobility similar to that of hemoglobin S in a newborn screening program” which appeared in the volume 35 number 2 issue of the Rev[r] ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.35 número3
... F: Female; M: Male; Hy: Hydroxyurea; Cy: Cytarabine; Mit: Mitoxantrone; HD: High dose chemotherapy; allo BMT: allogeneic Bone Marrow Transplantation; IM: imatinib; AML: Acute myeloid le[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número3
... After treating MM patients by transplantation, maintenance treatment with oral dexamethasone in isolation (40 mg/day for four days every 28 days) or dexamethasone (at the same dose) a[r] ... See full document
17
Rev. Bras. Hematol. Hemoter. vol.35 número3
... 5. Magalhães GL, Pelisson M, Colluço AG, Koti AN, Gelinski JR, Saito M, et al. Validação do sistema BactAlert utilizado para controle microbiológico de hemocomponentes no Hemocentro Regional de Londrina [Abstract 750]. ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número3
... control: positive; direct antiglobulin test (DAT - polyspeciic and monospeciic) positive; complement test: negative; red cell panel (to study and identify antibodies): positive, anti-E,[r] ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.35 número3
... Methods: This study compared serum lactate dehydrogenase levels in 27 patients with diffuse large B-cell lymphoma who relapsed after sustaining a complete response versus 87 patients w[r] ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.35 número3
... Conclusion : Chronic kidney disease patients on the transplant waiting list in Ceará, Brazil, display high rates of red cell (7.4%) and leukocyte (30.5%) alloimmunization.. In this samp[r] ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.35 número3
... Objective: The aims of this study were to assess the late reporting of incidents related to possible seroconversion in respect to age, marital status and ethnical background, annual var[r] ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.35 número3
... Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with subo[r] ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.35 número3
... Kidney dysfunction and beta S-haplotypes in patients with sickle cell disease.. Lilianne Brito da Silva Rocha Geraldo Bezerra da Silva Jn Elizabeth de Francesco Daher Hermano Alexandre L[r] ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.35 número3
... This study aimed to verify the relationship between the blood lipid and hematologic proiles with obesity in adolescents beginning multidisciplinary weight loss therapy.. Methods.[r] ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.35 número3
... Thiyagarajan et al. analyzed the clinical signiicance of the presence of HLA antibodies and donor-speciic antibodies before transplant and their impact on graft function, rejection episodes and graft survival. Using the ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número3
... In conclusion, there is a continuous need to work on hemovigilance; the laws and tools are in place, but there is still the need of establishing the correct awareness system in order [r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número3
... 68 years while on HU therapy was shown to be mainly due to ACS (35%), but also due to multiple organ failure, stroke, end- stage renal disease, sepsis, cardiac arrhythmia, and pulmonary embolism. In this trial, ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.35 número3
... For patients out of clinical trials there seems to be no evidence for the routine use of imaging scans or laboratory tests in the follow up after completing treatment (1).. The clinical[r] ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.35 número6
... Objective: To evaluate lipid peroxidation and Trolox equivalent antioxidant capacity in relation to serum iron and ferritin in beta thalassemia resulting from two different mutations ([r] ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.35 número6
... This study also reveals that all the hematological features of thalassemia minor have decreased to a lesser extent than in thalassemia major compared to normal healthy individuals.. Ho[r] ... See full document
2
temas relacionados